Imago BioSciences, Inc. Common stock
IMGO
IMGO was delisted on the 10th of January, 2023.
65 hedge funds and large institutions have $478M invested in Imago BioSciences, Inc. Common stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
15% more capital invested
Capital invested by funds: $417M → $478M (+$61.2M)
5% more funds holding
Funds holding: 62 → 65 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.72M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.45M |
| 3 |
BlackRock
New York
|
+$3.18M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$2.42M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.49M |
| 2 |
Goldman Sachs
New York
|
-$3.16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$848K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$571K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$429K |
IMGO Hedge Fund Activity: Q3 2022 in Review
65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Imago BioSciences, Inc. Common stock (IMGO) for Q3 2022, worth a combined $478M — up 15% from $417M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMGO positions and 4 closed out — a net gain of 3 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.72M. The largest seller was Woodline Partners, cutting an estimated $3.49M.
- 65 institutional investors held Imago BioSciences, Inc. Common stock (IMGO) as of Q3 2022, up from 62 in Q2 2022.
- Funds reported $478M of Imago BioSciences, Inc. Common stock stock for Q3 2022, up 15% quarter-over-quarter.
- 7 funds opened new Imago BioSciences, Inc. Common stock positions in Q3 2022 and 4 closed out, a net change of +3 holders.
- The largest Imago BioSciences, Inc. Common stock buyer in Q3 2022 was Vanguard Group, an estimated $3.72M added.
- The largest Imago BioSciences, Inc. Common stock seller in Q3 2022 was Woodline Partners, an estimated $3.49M sold.
Based on aggregated 13F filings for Q3 2022.